

19th July, 2012

Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai – 400 001

Dear Sir,

Re: Clause 41
Scrip Code: BSE – AJANTAPH 532331
NSE – AJANTPHARM EQ

Pursuant to Clause 41 of the Listing Agreement, we are enclosing herewith Unaudited Financial Results for the first quarter ended 30th June, 2012 duly signed by the Managing Director. These results were approved by the Board of Directors at their Meeting held on Thursday, 19th July, 2012.

We are also enclosing a copy of the Press Release to be published in newspapers.

Kindly acknowledge receipt.

Thanking You,

Yours faithfully,
For **AJANTA PHARMA LIMITED**



DEODATTA PANDIT
*G.M. - Legal &
Company Secretary*

Encl.: a/a

c.c. : National Stock Exchange of India,
Exchange Plaza, 5th Floor, Plot no. C/1, G Block,
Bandra Kurla Complex, Bandra (East),
Mumbai – 400 051

ajanta pharma limited

Regd. Office: 'Ajanta House', Charkop, Kandivli (W), Mumbai-67

Statement of Financial Results for the quarter ended 30th June, 2012

Particulars		3 months ended			₹ in Crores
		30/06/2012	31/03/2012	30/06/2011	31/03/2012
		Unaudited			Audited
1	Income from Operations				
	(a) Net Sales (Net of excise duty)	171.79	172.68	127.31	598.25
	(b) Other operating income	2.26	3.42	1.16	6.02
	Total Income from Operations (net)	174.05	176.10	128.47	604.27
2	Expenditure				
	(a) Cost of materials consumed	44.38	78.01	45.84	230.29
	(b) Purchases of stock-in-trade	5.28	6.02	4.47	20.47
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	15.48	(18.84)	(3.43)	(32.99)
	(d) Employees benefits expense	25.63	24.89	20.09	87.17
	(e) Depreciation and amortisation expense	7.78	8.24	6.64	30.68
	(f) Other expenses	46.19	46.18	39.06	167.39
	Total expenses	144.74	144.50	112.67	503.01
3	Profit from operations before other income, finance costs & tax (1-2)	29.31	31.60	15.80	101.26
4	Other Income	9.76	(2.01)	0.57	1.21
5	Profit from ordinary activities before finance costs & tax (3+4)	39.07	29.59	16.37	102.47
6	Finance costs	15.95	(1.66)	2.81	22.72
7	Profit from ordinary activities before tax (5-6)	23.12	31.25	13.56	79.75
8	Tax Expense	3.54	7.65	1.03	13.26
9	Net Profit for the period (7-8)	19.58	23.60	12.53	66.49
10	Paid-up Equity Share Capital (Face value of ₹10/- each)	11.80	11.80	11.80	11.80
11	Reserve excluding Revaluation Reserves	NA	NA	NA	260.04
12	Earnings Per Share (of ₹10/- each) (not annualised):				
	(a) Basic - in ₹	16.72	20.15	10.70	56.79
	(b) Diluted - in ₹	16.68	20.11	10.70	56.66
A	PARTICULARS OF SHAREHOLDING				
1	Public Shareholding				
	- Number of shares	3,297,120	3,497,230	3,884,879	3,497,230
	- Percentage of shareholding	28.16%	29.87%	33.18%	29.87%
2	Promoters and promoter group shareholding				
a)	Pledged/Encumbered				
	- Number of shares	550,000	550,000	200,000	550,000
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	6.54%	6.70%	2.56%	6.70%
	- Percentage of shares (as a % of the total share capital of the company)	4.70%	4.70%	1.71%	4.70%
b)	Non-encumbered				
	- Number of shares	7,861,380	7,661,270	7,623,621	7,661,270
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	93.46%	93.30%	97.44%	93.30%
	- Percentage of shares (as a % of the total share capital of the company)	67.14%	65.43%	65.11%	65.43%
B	INVESTOR COMPLAINTS	3 Months ended 30/06/2012			
	Pending at the beginning of the quarter and remaining unresolved at the end of the quarter	Nil			
	Received and disposed off during the quarter	10			
Notes :					
1. Other income includes forex gain on debtors and finance cost includes forex gain \ loss on loans.					
2. Above results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 19th July, 2012.					
3. Statutory Auditors have carried out Limited Review of the above results.					
4. The company has one segment of activity namely, pharmaceuticals.					
5. Previous period's figures have been regrouped wherever necessary.					
				By order of the Board For Ajanta Pharma Ltd.	
					
				Yogesh M. Agrawal Managing Director	
Mumbai, 19th July, 2012					

COMPANY CONTACT:

Ajanta House,
Charkop, Kandivli (West),
Mumbai - 400 067
+91 22 66061000
www.ajantapharma.com

INVESTOR CONTACTS:

Deodatta Pandit
Company Secretary
+91 22 66061203
deodatta.pandit@ajantapharma.com

Press Release**Ajanta Pharma posts healthy growth**

Net Profit up 56%, Revenue up 35%
(Standalone)

Mumbai - (July 19, 2012) - Ajanta Pharma Limited, a specialty focused pharmaceutical formulation company, has continued its growth during the first quarter of current financial year 2012-13. Company's Net Profit grew by 56% at Rs.19.58crs against Rs.12.53crs for the first quarter last financial year. Revenue for the first quarter of financial year 2012-13 stood at Rs.174.05crs (Rs.128.80crs), a growth of 35% over the previous year.

During the quarter, finance cost has seen a major jump at Rs.15.95crs as against Rs.2.80crs during last year same period. This includes losses on Foreign Currency loans borrowed by the company. However, the same is set off to major extent through a gain on foreign currency debtors outstanding, which is included in other income, which has gone up to Rs.9.76crs against Rs.0.23crs in the previous year same period. This is in line with the policy followed by the company for natural hedging of its foreign currency exposures.

The Company's Board of Directors have fixed the record date of 10th August 2012 for splitting of its equity share of Rs.10 each in to 2 equity shares of Rs.5 each.

About Ajanta Pharma Limited

Ajanta Pharma is a speciality pharmaceutical formulation company, having leading brands in the therapeutic segments of Ophthalmology, Dermatology and Cardiology. Many of the company's products are first of its kind and are leading in their sub therapeutic segments. Company exports its products to more than 25 countries and established strong brand equity in these markets. For last 10 years, company's consolidated performance has been excellent with CAGR of 22% in sales and 46% in net profit.

Ajanta Pharma has its State of the Art R&D centre located at Mumbai, with more than 200 scientists working for formulation development. The company has world class manufacturing facilities - four located in India and one at Mauritius. One of the manufacturing facilities at Aurangabad is approved by US FDA, UK MHRA and World health organisation (WHO), apart from having the approval from FDA of many other countries. Company is in the process of setting up two more manufacturing facilities in India, one for regulated markets and another for domestic and rest of the world markets.

